VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
ORKA
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
ORKAOruka Therapeutics, Inc.
$96.32$5.8B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksORKACash Flow

Oruka Therapeutics, Inc. (ORKA) Cash Flow Statement

21Y historyFree accessUpdated daily

Operating cash flow of -$44.3M in 2026Q3 tracks net loss closely at an OCF-to-net-income ratio of 0.89, with no dividends, buybacks, or acquisitions, so all capital raised is being consumed by operations.

Income StatementBalance SheetCash FlowRatios

ORKA Cash Flow Statement

Annual statement

ORKA Cash Flow Statement

Oruka Therapeutics, Inc. (ORKA) cash flow statement — 21-year operating, investing & financing cash flows

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05
Cash from Operations-123.64M-88.21M-57.84M--10.91M-18.76M-7.72M-4.8M-8.24M-17.47M-14.99M-10.53M-9.41M-5.29M-4.08M-6.96M-8.32M-41.73M-18.4M-45.96M-37.06M-59.03M
Operating CF Margin %--------------------98.07%-953.19%-10832.11%
Operating CF Growth %-181.45%-52.51%--41.84%-142.87%-60.9%41.76%52.82%-16.58%-42.27%-11.99%-77.87%-29.67%41.4%16.4%80.05%-126.76%59.96%-24.01%37.22%-
Net Income-152.57M-105.43M-83.72M--9.93M-19.32M-9.74M-5.48M-7.93M-18.49M-16.44M-11.45M-9.69M-6.94M-4.32M-5.36M-8.42M-9.14M-19.43M-12.3M-132.78M-71.61M
Depreciation & Amortization163K83K27K-114K91K93K89K22K27K24K19K12K26K43K602K338K457K220K2.34M3.18M2.67M
Stock-Based Compensation9.13M00-000000000000000000
Deferred Taxes000-0000000000000-2.28M0000
Other Non-Cash Items14.93M19.7M14.27M-561K497K43K151K275K906K1.03M788K714K283K306K-1.68M191K-17.63M670K12.55M38.76M-33K
Working Capital Changes4.71M-2.56M11.59M--1.66M-28K1.88M441K-608K85K400K104K-443K1.34M-107K-521K-433K-13.13M140K-48.55M53.77M9.94M
Change in Receivables000-0000000000000007.97M-7.35M-1.07M
Change in Inventory000-00000000000000000360K
Change in Payables12.17M693K3.46M--783K-411K1.1M188K-392K-583K000532K-195K-128K-145K-2.46M-865K-4.27M2.11M1.81M
Cash from Investing-606.8M-96.75M-330.13M--2K-43K-19K-4K3.05M12.93M-16.41M-11K-19K-32K02.01M265K45.63M-2.52M21.09M-62.06M-1.18M
Capital Expenditures-219K-209K-189K--2K-43K-19K-4K-4K-3K-12K-11K-19K-32K0-19K-4K-185K-1.34M-381K-2.44M-2.57M
CapEx % of Revenue-------------------0.81%62.81%471.56%
Acquisitions000-0000000000025K6K322K5K136K540K0
Investments----------------------
Other Investing000-000000000002M00-1.19M-6M00
Cash from Financing830.71M170.31M449.54M-023.09M48.45M6.56M3.1M5.85M033.99M8.02M19.16M1.05M3.87M7.32M-3.89M12.8M-3.4M121.69M81.16M
Debt Issued (Net)000-00-408K-349K00000-174K-134K00-4M12.75M-3.83M-5.59M-3.38M
Equity Issued (Net)830.71M170.31M449.54M-023.09M48.86M6.91M3.42M6.1M034.19M8.2M19.33M1.19M4.02M7.66M114K54K426K130.04M84.35M
Dividends Paid000-000000000000000000
Share Repurchases000-000000000000000000
Other Financing000-0000-311K-256K0-193K-179K00-146K-338K000-2.75M191K
Net Change in Cash100.27M-14.64M24.14M--10.91M4.29M40.71M1.75M-2.09M1.3M-31.4M23.45M-1.4M13.84M-3.02M-1.08M-738K23K-24.32M-28.27M22.57M37.76M
Free Cash Flow-123.86M-88.42M-58.03M--10.91M-18.8M-7.74M-4.8M-8.25M-17.48M-15M-10.54M-9.43M-5.32M-4.08M-6.98M-8.33M-41.91M-19.75M-46.34M-39.5M-61.6M
FCF Margin %--------------------98.89%-1016%-11303.67%
FCF Growth %-46.41%-52.38%--41.96%-142.83%-61.17%41.74%52.8%-16.51%-42.24%-11.88%-77.16%-30.46%41.56%16.21%80.13%-112.26%57.39%-17.31%35.88%-
FCF per Share-1.73-1.94-3.46--0.76-1.35-1.64-43.64-128.64-361.85-357.31-362.16-695.11-932.19-2774.15-6309.22-8881.82-53609.64-999999.00-157646.26-139302.30-270782.02
FCF Conversion (FCF/Net Income)0.81x0.84x0.69x-1.10x0.97x0.79x0.88x1.04x0.94x0.91x0.92x0.97x0.76x0.94x1.30x0.99x4.57x0.95x3.74x0.28x0.82x
Interest Paid000-000000000000000000
Taxes Paid000-000000000000000000

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Dilutive financing dependence risk

Cash Losses Track Accounting Losses Closely

According to recent SEC filings, ORKA's operating cash flow of -$44.3M in 2026Q3 against a net loss of -$50.0M yields an OCF-to-net-income ratio of 0.89, indicating that most reported losses are consuming cash rather than being offset by non-cash charges.

The gap between net loss and operating cash flow is narrower than the $9.1M of stock-based compensation alone would imply, suggesting that the remaining non-cash items are modest and the loss is largely a real cash outflow. Over the ten quarters provided, the ratio has ranged from 0.12 to 1.22, with the 2024Q2 figure reflecting a timing distortion rather than a durable pattern. Investors should monitor whether the ratio stabilizes near 0.7 to 0.9, which would indicate that the cash burn is structural and driven by clinical spending rather than accounting noise.

Free Cash Outflow Accelerating With Clinical Spend

Based on reported figures, ORKA's free cash flow deteriorated from -$2.6M in 2024Q2 to -$44.4M in 2026Q3, a roughly seventeen-fold increase in quarterly cash consumption over six quarters.

Because the company reports no revenue, free cash flow margin is data unavailable, and the absolute burn rate is the only meaningful trajectory measure. The acceleration appears consistent with the step-up in R&D expense noted in the income statement analysis, suggesting late-stage or expanded trial activity. This trend may indicate that the current cash balance of roughly $46.9M covers little more than one additional quarter at the latest burn rate, warranting close attention to financing timing.

Negligible Capital Intensity Confirms Asset-Light Model

As reported in financial statements, ORKA's capital expenditures remained between $0 and $171K per quarter across the period, a rounding error relative to its $44.3M quarterly operating cash outflow.

The minimal capex profile is consistent with a company that outsources discovery to Paragon and relies on contract manufacturers rather than owned production facilities. D&A of roughly $20K to $49K per quarter corroborates the absence of a meaningful fixed asset base. This suggests that the cash economics are driven almost entirely by operating expense rather than by capital formation, and that the risk profile is one of execution spending rather than balance sheet asset depreciation.

No Capital Returned, All Cash Consumed by Operations

Based on reported figures, ORKA paid no dividends, executed no share repurchases, and recorded no net acquisition outflows across the ten quarters, so all deployed cash went toward operating activities.

The absence of shareholder distributions is expected for a pre-revenue clinical-stage company and does not in itself signal weakness. However, the absence of capital returns combined with a burn rate that rose sharply means every dollar raised is being consumed by operations, leaving no buffer. Investors should monitor future financing terms, since the next capital raise will likely determine dilution levels and the company's ability to reach its next clinical readout.

Cumulative Losses Dwarf Reported Cash Position

Based on reported figures, the cumulative operating cash outflow across the ten quarters exceeds $260M, against a reported cash balance of approximately $46.9M, implying the company has depended heavily on external financing to date.

The cumulative gap between net income and operating cash flow is relatively consistent in direction, with losses in every quarter, so the divergence is primarily a question of scale rather than accounting quality. The historical financing required to fund this burn is not fully visible in the provided data, so the source and timing of past capital raises remain data unavailable. This pattern suggests the business model is structurally dependent on capital markets until a commercial product or partnership generates cash.

Non-Cash Charges Could Obscure True Burn

Based on reported figures, stock-based compensation of $9.1M in 2026Q3 and $10.2M in 2025Q3 may flatter the operating cash picture, so underlying cash needs could differ from headline burn depending on how awards are settled.

Stock-based compensation is excluded from operating cash outflow, so the reported burn understates the economic cost of retaining specialized scientific talent. If equity awards are increasingly replaced with cash bonuses or retention payments, operating cash burn could rise beyond the current trajectory. Investors should monitor the composition of R&D and SG&A expense and any shift in compensation mix, as this warrants further investigation rather than being treated as a settled conclusion.

ORKA — Frequently Asked Questions

Quick answers to the most common questions about buying ORKA stock.

How much cash does Oruka Therapeutics, Inc. (ORKA) generate from operations?

Oruka Therapeutics, Inc. (ORKA) generated $-88.2M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Oruka Therapeutics, Inc.'s free cash flow?

Oruka Therapeutics, Inc. (ORKA) reported negative free cash flow of $88.4M in 2025, indicating capital requirements exceeded cash from operations.

What is Oruka Therapeutics, Inc.'s capital expenditure (CapEx)?

Oruka Therapeutics, Inc. (ORKA) spent $0.2M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.